63 research outputs found
Do Competitive Disadvantages Really Arise from 'Over Complying'?: Proposed Basel III Leverage and Supplementary Leverage Ratios Re-Visited
Molecular detection of enteropathogenic Escherichia coli in asymptomatic captive psittacines
Simultaneous analysis of T helper subsets (Th1, Th2, Th9, Th17, Th22, Tfh, Tr1 and Tregs) markers expression in periapical lesions reveals multiple cytokine clusters accountable for lesions activity and inactivity status
TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Introduction: Rheumatoid arthritis (RA) is associated with focal and systemic bone loss involving cytokines such as RANKL and TNF-a.
RANK-L promotes focal and systemic osteoporosis, whereas osteoprotegerin (OPG) inhibits bone resorption. Although anti-TNF-a
antibodies (anti-TNF-a Ab) decrease joint inflammation and bone erosions, their effects on bone loss are unknown. The aim of this study was
to evaluate the effects of OPG and anti-TNF-a Ab, separately or in combination, on inflammation and bone remodeling in collagen-induced
arthritis (CIA), a model of RA. Methods: DBA/1 mice (n = 28) were immunized with bovine type II collagen and treated with OPG-Fc or
anti-TNF-a Ab or both, or saline. One group of mice (n = 7) was not immunized (naive group). Urinary deoxypyridinoline (D-pyr) and
whole-body bone mineral density (BMD) were measured at baseline and at sacrifice. Histomorphometric parameters were evaluated at the
femoral metaphysis. Results: Anti-TNF-a Ab, but not OPG, decreased the clinical arthritis score (P b 0.02 vs. saline) and the histological
score of inflammation. The BMD change from baseline to sacrifice (DBMD) was significantly smaller in CIA mice than naive mice. OPG
and anti-TNF-a Ab significantly increased DBMD versus saline, and the effect was greater with OPG (P b 0.003). DD-pyr decreased by 65%
with OPG and 13% with anti-TNF-a Ab. Compared with saline, OPG increased trabecular bone volume (BV/TV) (P b 0.02), decreased
trabecular separation (P b 0.02), and decreased the bone formation rate (BFR) (P b 0.01). Anti-TNF-a Ab produced no significant changes in
bone volume or trabecular separation but increased trabecular thickness (P b 0.02 vs. saline) to a value close to that in naive mice, suggesting
preservation of bone formation. No additive effects of OPG and anti-TNF-a Ab were found. Conclusions: Systemic OPG and anti-TNF-a Ab
therapy prevented bone loss in CIA mice through distinct mechanisms involving decreased bone resorption and preserved bone formation.
Combining these two agents might help to prevent bone loss in inflammatory diseases
What predicts initiation of osteoporosis treatment after fractures: education, organisation or patients' characteristics ?
- …